Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms

Article ID	Journal	Published Year	Pages	File Type
8536771	Pharmacology & Therapeutics	2018	15 Pages	PDF

Abstract

Thus, arrhythmias appear to be an underappreciated adverse effect of anticancer agents and the incidence, significance and underlying mechanisms are now being investigated.

Keywords

EGFR BCR-ABL Histone deacetylases inhibitors CLL HDIs CTLA4 CD20 APD LGE FDA IL-2 CYP17 GnRH RAF NAC PI3K HER2 5-FU breakpoint cluster region-Abelson CDK DAMPs PD-1 PDL-1 APL EMA Btk Implantable cardioverter defibrillator N-acetyl-cysteine NFκB ALK European Medicines agency late gadolinium enhancement Interleukin-2 Bruton tyrosine kinase Left ventricular ICD Food and Drug Administration nuclear factor kappa B phosphoinositide 3-kinase 5-fluorouracil Atrial fibrillation Anaplastic lymphoma kinase Chronic lymphocytic leukemia Acute promyelocytic leukemia MEK Action potential duration Programmed death 1 programmed death-ligand 1 Kinase inhibitors damage-associated molecular pattern molecules gonadotrophin releasing hormone KIS cyclin-dependent kinase Human epidermal growth factor receptor 2 Epidermal growth factor receptor

Related Topics

Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Pharmacology

Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms

Authors

Joachim Alexandre, Javid J. Molsehi, Kevin R. Bersell, Christian Funck-Brentano, Dan M. Roden, Joe-Elie Salem,